Key result
Late-onset durvalumab-associated myocarditis, occurring seven months after initiation for non-small-cell lung cancer, was successfully treated with corticosteroid therapy.
Population
A 66-year-old man with locally advanced NSCLC who developed durvalumab-associated myocarditis
Comparison
Cessation of durvalumab and corticosteroid therapy
Design
Case report
Authors
Loading...
May warrant myocarditis vigilance with durvalumab in NSCLC; leaves open incidence, predictors, and surveillance needs.
Case Report (n=1)
This case highlights the potential for late-onset myocarditis following durvalumab administration and its successful management with corticosteroids.
Maetani et al. (2021) conducted a case report in Durvalumab-associated myocarditis in non-small-cell lung cancer (n=1). Corticosteroid therapy was evaluated on Clinical recovery from myocarditis. Late-onset durvalumab-associated myocarditis, occurring seven months after initiation for non-small-cell lung cancer, was successfully treated with corticosteroid therapy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: